JNJ-89402638 Phase 2 Study Initiated for Metastatic Colorectal and Gastric Cancers
A Phase 2 study is underway to assess the safety and optimal administration of JNJ-89402638 in mCRC and mGAC patients.
Phase II
metastatic colorectal cancer
Status
Initiated
Sponsor
JNJ-89402638
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The initiation of the Phase 2 study for JNJ-89402638 is significant as it could redefine treatment protocols for metastatic colorectal and gastric cancers. Positive outcomes may enhance Janssen's competitive positioning against established therapies, particularly bevacizumab.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor results for RP2D determination and safety outcomes, as well as potential combination therapy efficacy.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.